1 March 2003 in European Journal of Cancer
ZNZora Nešković-Konstantinović
Zora Nešković-Konstantinović
DNDragica Nikolić-Vukosavljević
Dragica Nikolić-Vukosavljević
+1
1 May 2004 in Medical Hypotheses
DND Nikolić-Vukosavljević
ZNZ Nešković-Konstantinović
Z Nešković-Konstantinović
+3
1 January 2006 in Archive of Oncology
The main objective of this presentation is to review current knowledge regarding molecular mechanisms of Transforming Growth Factor-?1(TGF-?1) action in breast carcinogenesis. In addition, our recent results will be presented on TGF-?1 gene polymorphism and its relationship to TGF-?1 secretion in breast cancer (BC) patients. Special focus will be made on potential clinical applicability of TGF-?1 as a putative diagnostic, prognostic or predictive tool in BC detection and treatment. TGF-?1 has a complex multifunctional profile, with tumor suppressive effects in early stages of breast carcinogenesis, but progressive dominance of tumor promoting effects with transition to more advanced malignant states. Clarification of molecular mechanisms that control parallel processing of these opposing TGF-?1 activities might suggest new approaches for shifting the balance in favor of net tumor suppression. Now, a major challenge remains in more precisely defining TGF-?1 signaling pathways and their cancer-related alterations. Current dogma views human tumorigenesis as a molecular disruption of normal physiology through genetic, epigenetic, or somatic alterations. The genetic model offers biological plausibility to epidemiological studies that link the TGF-?1 gene polymorphism, at codon 10 due to Leu10Pro substitution in the signal peptide, with the risk of developing BC. The somatic mutations approach, provides an explanation for the TGF-?1 overexpression in advanced BC through mutations acquired in the components of Smad-mediated TGF-?1 signaling pathway. The available results indicate decreased T?RII (TGF-?1 receptor-type II) expression, rare T?RII gene mutations, but no mutations in Smad2 and Smad4 genes, in advanced BC patients. .
1 January 2002 in Archive of Oncology
ZNZora Neskovic-Konstantinovic
Zora Neskovic-Konstantinovic
DNDragica Nikolic-Vukosavljevic
Dragica Nikolic-Vukosavljevic
+2
TGF-beta1 is a pluripotent cytokine with diverse effects in the normal development of mammary glands, and in the development of malignant tumors of the breast. The aim of the study was to determine the levels of TGF-beta1 in the group of advanced breast cancer, in which increased TGF-beta1 levels were most likely to be expected. TGF-beta1 levels were also compared with estradiol levels. Our results suggested that TGF-beta1 synthesis may be regulated by estrogen or anti-estrogen through ER. Finding of increased TGF-beta1 levels, due to its possible role in predicting invasive phenotype in later phases of tumor progression, may indicate the tendency of tumor tissue towards autonomy.